
Early pancreatic cancer study reports tumour responses in 61-patient group
Revolution Medicines reported confirmed responses in 60.7% of participants given daraxonrasib with chemotherapy. A larger comparative trial is ongoing.
News in perspective.
Context. Clarity. Sources.

Revolution Medicines reported confirmed responses in 60.7% of participants given daraxonrasib with chemotherapy. A larger comparative trial is ongoing.